Pharmacologic agents for type 2 diabetes therapy and regulation of adipogenesis

Archives of Physiology and Biochemistry

Volumn 119, Issue 4, 2013, Pages 139-150

  Cignarelli, A ^a   Giorgino, F ^a   Vettor, R ^b  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Adipocyte; Adipose tissue; Anti diabetes drugs; Weight gain

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; INSULIN;

ADIPOGENESIS; ADIPOSE TISSUE; ANIMAL; ARTICLE; DRUG EFFECT; HUMAN; LIPOGENESIS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY;

ADIPOGENESIS; ADIPOSE TISSUE; ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPOGENESIS;

EID: 84884802424     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.3109/13813455.2013.796996     Document Type: Article

References (168)

1. Abbott WG, Foley, JE. (1987). Comparison of body composition, adipocyte size, and glucose and insulin concentrations in Pima Indian and Caucasian children. Metabolism, 36:576-9
2. Accili D, Taylor SI. (1991). Targeted inactivation of the insulin receptor gene in mouse 3T3-L1 fibroblasts via homologous recombination. Proc Natl Acad Sci USA, 88:4708-12
3. Adams M, Montague CT, Prins JB, et al. (1997). Activators of peroxisome proliferator-Activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest, 100: 3149-53
4. Aguilar-Bryan L, Nichols CG, Wechsler SW, et al. (1995). Cloning of the beta cell high-Affinity sulfonylurea receptor: A regulator of insulin secretion. Science, 268:423-6
5. Alexandre KB, Smit AM, Gray IP, Crowther NJ. (2008). Metformin inhibits intracellular lipid accumulation in the murine pre-Adipocyte cell line, 3T3-L1. Diabetes, Obesity & Metab, 10:688-90
6. An Z, Wang H, Song P, et al. (2007). Nicotine-induced activation of AMP-Activated protein kinase inhibits fatty acid synthase in 3T3L1 adipocytes: A role for oxidant stress. J Biol Chem, 282:26793-801
7. Anedda A, Rial E, Gonzalez-Barroso MM. (2008). Metformin induces oxidative stress in white adipocytes and raises uncoupling protein 2 levels. J Endocrin, 199:33-40
8. Arakawa M, Ebato C, Mita T, et al. (2009). Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents. Biochem Biophys Res Commun, 390:809-14
9. Arner P, Pettersson A, Mitchell PJ, et al. (2008). FGF21 attenuates lipolysis in human adipocytes-A possible link to improved insulin sensitivity. FEBS Lett, 582:1725-30
10. Arner P, Bernard S, Salehpour M, et al. (2011). Dynamics of human adipose lipid turnover in health and metabolic disease. Nature, 478: 110-13
11. Assimacopoulos-Jeannet F, Brichard S, Rencurel F, et al. (1995). In vivo effects of hyperinsulinemia on lipogenic enzymes and glucose transporter expression in rat liver and adipose tissues. Metabolism, 44:228-33
12. Bakan I, Laplante M. (2012). Connecting mTORC1 signaling to SREBP-1 activation. Curr Opin Lipidol, 23:226-34
13. Birkenfeld AL, Boschmann M, Moro C, et al. (2005). Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J Clin Endocrinol Metab, 90:3622-8
14. Blüher M, Michael MD, Peroni OD, et al. (2002). Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell, 3:25-38
15. Boden G, Homko C, Mozzoli M, et al. (2005). Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients. Diabetes, 54:880-5
16. Boden G, Cheung P, Mozzoli M, Fried SK. (2003). Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. Metabolism, 52:753-9
17. Bogacka I, Ukropcova B, McNeil M, et al. (2005). Structural and functional consequences of mitochondrial biogenesis in human adipocytes in vitro. J Clin Endocrinol Metab, 90:6650-6
18. Böhm A, Staiger H, Hennige AM, et al. (2008). Effect of insulin detemir, compared to human insulin, on 3T3-L1 adipogenesis. Regul Peptides, 151:160-3
19. Bolen S, Feldman L, Vassy J, et al. (2007). Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med, 147:386-99
20. Boucher J, Mori MA, Lee KY, et al. (2012). Impaired thermogenesis and adipose tissue development in mice with fat-specific disruption of insulin and IGF-1 signalling. Nature Comm, 3:902
21. Cao Z, Umek RM, McKnight SL. (1991). Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Dev, 5:1538-52
22. Caton PW, Kieswich J, Yaqoob MM, et al. (2011). Metformin opposes impaired AMPK and SIRT1 function and deleterious changes in core clock protein expression in white adipose tissue of genetically-obese db/db mice. Diabetes, Obesity & Metab, 13:1097-104
23. Challa TD, Beaton N, Arnold M, et al. (2012). Regulation of adipocyte formation by GLP-1/GLP-1R signaling. J Biol Chem, 287:6421-30
24. Chao L, Marcus-Samuels B, Mason, MM, et al. (2000). Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest, 106:1221-8
25. Chapman TM, Perry CM. (2004). Insulin detemir: A review of its use in the management of type 1 and 2 diabetes mellitus. Drugs, 64: 2577-95
26. Choi S-S, Cha B-Y, Lee Y-S, et al. (2009). Magnolol enhances adipocyte differentiation and glucose uptake in 3T3-L1 cells. Life Sci, 84: 908-14
27. Choi S-S, Cha B-Y, Iida K, et al. (2011). Artepillin C, as a PPARg ligand, enhances adipocyte differentiation and glucose uptake in 3T3-L1 cells. Biochem Pharmacol, 81:925-33
28. Cignarelli A, Barbaro M, Nigro P, et al. (2011). Insulin detemir induced less adipogenesis and less lipid droplets accumulation than human insulin in human adipose stem cells. Diabetes, 60:A408-42
29. Cipolletta D, Feuerer M, Li A, et al. (2012). PPAR-g is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature, 486:549-53
30. Coppack SW, Patel JN, Lawrence VJ. (2001). Nutritional regulation of lipid metabolism in human adipose tissue. Exp Clin Endocrinol Diabetes, 109:S202-14
31. Cornelius P, MacDougald OA, Lane MD. (1994). Regulation of adipocyte development. Annu Rev Nutr, 14:99-129
32. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW. (1994). Glucagonlike peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest, 93:2263-6
33. Daval M, Diot-Dupuy F, Bazin R, et al. (2005). Anti-lipolytic action of AMP-Activated protein kinase in rodent adipocytes. J Biol Chem, 280: 25250-7
34. De Souza CJ, Eckhardt M, Gagen K, et al. (2001). Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes, 50:1863-71
35. Deeb SS, Fajas L, Nemoto M, et al. (1998). A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet, 20:284-7
36. Dimitriadis G, Mitrou P, Lambadiari V, et al. (2006). Glucose and lipid fluxes in the adipose tissue after meal ingestion in hyperthyroidism. J Clin Endocrinol Metab, 91:1112-18
37. Ducluzeau P-H, Perretti N, Laville M, et al. (2001). Regulation by insulin of gene expression in human skeletal muscle and adipose tissue: Evidence for specific defects in Type 2 diabetes. Diabetes, 50: 1134-42
38. Duvel K, Yecies JL, Menon S, et al. (2010). Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell, 39:171-83
39. El-Mir MY, Nogueira V, Fontaine E, et al. (2000). Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem, 275:223-8
40. Fischer M, Timper K, Radimerski T, et al. (2010). Metformin induces glucose uptake in human preadipocyte-Derived adipocytes from various fat depots. Diabetes, Obesity & Metab, 12:356-9
41. Foellmi-Adams LA, Wyse BM, Herron D, et al. (1996). Induction of uncoupling protein in brown adipose tissue. Synergy between norepinephrine and pioglitazone, an insulin-sensitizing agent. Biochem Pharmacol, 52:693-701
42. Fonseca V. (2003). Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med, 115:42S-8S.
43. Foretz M, Guichard C, Ferre P, Foufelle F. (1999). Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc Natl Acad Sci USA, 96:12737-42
44. Frayn K. (2002). Adipose tissue as a buffer for daily lipid flux. Diabetologia, 45:1201-10
45. Freisleben HJ, Ruckert S, Wiernsperger N, Zimmer G. (1992). The effects of glucose, insulin and metformin on the order parameters of isolated red cell membranes. An electron paramagnetic resonance spectroscopic study. Biochem Pharmacol, 43:1185-94
46. Fukuen S, Iwaki M, Yasui A, et al. (2005). Sulfonylurea agents exhibit peroxisome proliferator-Activated receptor gamma agonistic activity. J Biol Chem, 280:23653-9
47. Fukui Y, Masui S, Osada S, et al. (2000). A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice. Diabetes, 49:759-67
48. Gao H, Wang X, Zhang Z, et al. (2007). GLP-1 amplifies insulin signaling by up-regulation of IRbeta, IRS-1 and Glut4 in 3T3-L1 adipocytes. Endocrine, 32:90-5
49. García-Escobar E, Rodriguez-Pacheco F, Haro-Mora JJ, et al. (2011). Effect of insulin analogues on 3t3-l1 adipogenesis and lipolysis. Euro J Clin Invest, 41:979-86
50. Gillies PS, Figgitt DP, Lamb HM. (2000). Insulin glargine. Drugs, 59: 253-60
51. Gonzalez-Barroso MM, Anedda A, Gallardo-Vara E, et al. (2012). Fatty acids revert the inhibition of respiration caused by the antidiabetic drug metformin to facilitate their mitochondrial beta-oxidation. Biochimica et Biophysica Acta, 1817:1768-75
52. Granneman JG, Moore H-PH. (2008). Location, location: Protein trafficking and lipolysis in adipocytes. Trends Endocrinol Metab, 19:3-9
53. Gregoire FM, Smas CM, Sul HEIS. (1998). Understanding adipocyte differentiation. Physiolog Rev, 78:783-809
54. Gribble FM, Ashcroft FM. (2000). Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism, 49:3-6
55. Grisouard J, Timper K, Radimerski TM, et al. (2010). Mechanisms of metformin action on glucose transport and metabolism in human adipocytes. Biochem Pharmacol, 80:1736-45
56. Hajduch EJ, Guerre-Millo MC, Hainault IA, et al. (1992). Expression of glucose transporters (GLUT 1 and GLUT 4) in primary cultured rat adipocytes: Differential evolution with time and chronic insulin effect. J Cell Biochem, 49:251-8
57. Hallakou S, Doaré L, Foufelle F, et al. (1997). Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes, 46:1393-9
58. Hara K, Okada T, Tobe K, et al. (2000). The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Comm, 271:212-16
59. Hardie DG. (2006). Neither LKB1 nor AMPK are the direct targets of metformin. Gastroenterology, 131:973; author reply 974-5
60. Hauner H. (2002). The mode of action of thiazolidinediones. Diabetes Metab Res Rev, 18:S10-5
61. He W, Barak Y, Hevener A, et al. (2003). Adipose-specific peroxisome proliferator-Activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci USA, 100: 15712-17
62. Hwang CS, Loftus TM, Mandrup S, Lane MD. (1997). Adipocyte differentiation and leptin expression. Annu Rev Cell Dev Biol, 13: 231-59
63. Idris I, Patiag D, Gray S, Donnelly R. (2002). Exendin-4 increases insulin sensitivity via a PI-3-kinase-Dependent mechanism: Contrasting effects of GLP-1. Biochem Pharmacol, 63:993-6
64. Inukai K, Watanabe M, Nakashima Y, et al. (2005). Glimepiride enhances intrinsic peroxisome proliferator-Activated receptor-gamma activity in 3T3-L1 adipocytes. Biochem Biophys Res Comm, 328:484-90
65. Jacobs DB, Jung CY. (1985). Sulfonylurea potentiates insulin-induced recruitment of glucose transport carrier in rat adipocytes. J Biol Chem, 260:2593-6
66. Jaworski K, Sarkadi-Nagy E, Duncan RE, et al. (2007). Regulation of triglyceride metabolism. IV. Hormonal regulation of lipolysis in adipose tissue. Am J Physiol Gastrointest Liver Physiol, 293:1-4
67. Kahn BB, Flier JS. (2000). Obesity and insulin resistance. J Clin Invest, 106:473-81
68. Kelly IE, Han TS, Walsh K, Lean ME. (1999). Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care, 22:288-93
69. Kersten S. (2001). Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Reports, 2:282-6
70. Kim JB, Sarraf P, Wright M, et al. (1998). Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J Clin Invest, 101:1-9
71. Kim JJ, Li P, Huntley J, et al. (2009). FoxO1 haploinsufficiency protects against high-fat diet-induced insulin resistance with enhanced peroxisome proliferator-Activated receptor gamma activation in adipose tissue. Diabetes, 58:1275-82
72. Kliewer SA, Xu HE, Lambert MH, Willson TM. (2001). Peroxisome proliferator-Activated receptors: From genes to physiology. Recent Prog Horm Res, 56:239-63
73. Kos K, Baker AR, Jernas M, et al. (2009). DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue. Diabetes, Obesity & Metab, 11:285-92
74. Koutnikova H, Cock T-A, Watanabe M, et al. (2003). Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR gamma hypomorphic mice. Proc Natl Acad Sci USA, 100: 14457-62
75. Kurtzhals P, Schaffer L, Sorensen A, et al. (2000). Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogues designed for clinical use. Diabetes, 49:999-1005
76. Kushner RF, Sujak M. (2009). Prevention of weight gain in adult patients with type 2 diabetes treated with pioglitazone. Obesity (Silver Spring, MD), 17:1017-22
77. Lafontan M, Moro C, Berlan M, et al. (2008). Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab, 19: 130-7
78. Lamers D, Famulla S, Wronkowitz N, et al. (2011). Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes, 60:1917-25
79. Lane MD, Flores-Riveros JR, Hresko RC, et al. (1990). Insulin-receptor tyrosine kinase and glucose transport. Diabetes Care, 13:565-75
80. Langin D. (2006). Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome. Pharmacol Res, 53:482-91
81. Lee KW, Ku YH, Kim M, et al. (2011). Effects of sulfonylureas on peroxisome proliferator-Activated receptor g activity and on glucose uptake by thiazolidinediones. Diabetes & Metab J, 35:340-7
82. Lehmann JM, Moore LB, Smith-Oliver TA, et al. (1995). An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferatoractivated receptor gamma (PPAR gamma). J Biol Chem, 270: 12953-56
83. Lenhard JM, Kliewer SA, Paulik MA, et al. (1997). Effects of troglitazone and metformin on glucose and lipid metabolism: Alterations of two distinct molecular pathways. Biochem Pharma, 54:801-8
84. Liao W, Nguyen MTA, Yoshizaki T, et al. (2007). Suppression of PPARgamma attenuates insulin-stimulated glucose uptake by affecting both GLUT1 and GLUT4 in 3T3-L1 adipocytes. Am J Phys Endocrin Metab, 293:E219-27
85. Lu M, Wan M, Leavens KF, et al. (2012). Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat Med, 18:388-95
86. Lutz, T.A. (2012). Effects of amylin on eating and adiposity. Handb Exp Pharmacol 209, 231-50
87. MacDougald OA, Lane MD. (1995). Transcriptional regulation of gene expression during adipocyte differentiation. Annu Rev Biochem, 64: 345-73
88. Magun R, Burgering BM, Coffer PJ, et al. (1996). Expression of a constitutively activated form of protein kinase B (c-Akt) in 3T3-L1 preadipose cells causes spontaneous differentiation. Endocrinology, 137:3590-3
89. Mandrup S, Lane MD. (1997). Regulating adipogenesis. J Biol Chem, 272:5367-70
90. Mannucci E, Rotella CM. (2008). Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk. Nutr Metab Cardiovasc Dis, 18:639-45
91. Martin G. (1997). Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem, 272:28210-17
92. Matsusue K, Haluzik M, Lambert G, et al. (2003). Liver-specific disruption of PPARgamma in leptin-Deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest, 111:737-47
93. Mayer P, Haas B, Celner J, et al. (2011). Glitazone-like action of glimepiride and glibenclamide in primary human adipocytes. Diabetes, Obesity & Metab, 13:791-9
94. Meneghini LF, Orozco-Beltran D, Khunti K, et al. (2011). Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab, 96: 3337-53
95. Merida E, Delgado E, Molina LM, et al. (1993). Presence of glucagon and glucagon-like peptide-1-(7-36)amide receptors in solubilized membranes of human adipose tissue. J Clin Endocrinol Metab, 77: 1654-7
96. Miegueu P, St-Pierre DH, Munkonda MN, et al. (2012). Amylin stimulates fatty acid esterification in 3T3-L1 adipocytes. Molec Cell Endocrin, 366:99-107
97. Miki H, Yamauchi T, Suzuki R, et al. (2001). Essential role of insulin receptor substrate 1 (IRS-1) and IRS-2 in adipocyte differentiation. Mol Cell Biol, 21:2521-32
98. Miki H, Namba M, Nishimura T, et al. (1996). Glucagon-like peptide-1(7-36)amide enhances insulin-stimulated glucose uptake and decreases intracellular cAMP content in isolated rat adipocytes. Biochimica et Biophysica Acta, 1312:132-6
99. Miller RE, Bhandari B. (1986). Glyburide action in cultured 3T3-L1 adipocytes. Biochem Int, 13:313-19
100. Miller RA, Chu Q, Xie J, et al. (2013). Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature, 494:256-60
101. Miyazaki Y, Mahankali A, Matsuda M, et al. (2002). Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab, 87:2784-91
102. Monami M, Marchionni N, Mannucci E. (2008). Long-Acting insulin analogueues versus NPH human insulin in type 2 diabetes: A metaanalysis. Diabetes Res Clin Prac, 81:184-9
103. Monami M, Marchionni N, Mannucci E. (2009). Long-Acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-Analysis. Diabetes, Obesity & Metab, 11:372-8
104. Moreno-Navarrete JM, Ortega FJ, Rodriguez-Hermosa J-I, et al. (2011). OCT1 Expression in adipocytes could contribute to increased metformin action in obese subjects. Diabetes, 60:168-76
105. Motojima K. (1998). Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-Activated receptor alpha and gamma activators in a tissue-And inducer-specific manner. J Biol Chem, 273:16710-14
106. Muller G, Satoh Y, Geisen K. (1995). Extrapancreatic effects of sulfonylureas-A comparison between glimepiride and conventional sulfonylureas. Diabetes Res Clin Pract, 28:115-37
107. Müller G, Wied S, Over S, Frick W. (2008). Inhibition of lipolysis by palmitate, H2O2 and the sulfonylurea drug, glimepiride, in rat adipocytes depends on cAMP degradation by lipid droplets. Biochemistry, 47:1259-73
108. Nakae J, Accili D. (1999). The mechanism of insulin action. J Pediatr Endocrinol Metab, 12:721-31
109. Nakano N, Miyazawa N, Sakurai T, et al. (2007). Gliclazide inhibits proliferation but stimulates differentiation of white and brown adipocytes. J Biochem, 142:639-45
110. Nathan, DM, Buse JB, Davidson MB, et al. (2009). Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 32:193-203
111. Nedergaard J, Petrovic N, Lindgren EM, et al. (2005). PPARgamma in the control of brown adipocyte differentiation. Biochim. Biophys Acta, 1740:293-304
112. Nielsen LL, Young AA, Parkes DG. (2004). Pharmacology of exenatide (synthetic exendin-4): A potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept, 117:77-88
113. Norris AW, Chen L, Fisher SJ, et al. (2003). Muscle-specific PPARgamma-Deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest, 112: 608-18
114. Oakes ND, Thalén PG, Jacinto SM, et al. (2001). Thiazolidinediones increase plasma-Adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes, 50: 1158-65
115. Okuno A, Tamemoto H, Tobe K, et al. (1998). Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest, 101:1354-61
116. Olefsky JM. (1976). Decreased insulin binding to adipocytes and circulating monocytes from obese subjects. J Clin Invest, 57: 1165-72
117. Olefsky JM. (2000). Treatment of insulin resistance with peroxisome proliferator-Activated receptor gamma agonists. J Clin Invest, 106: 467-72
118. Owen MR, Doran E, Halestrap AP. (2000). Evidence that metformin exerts its anti-Diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J, 348 Pt 3:607-14
119. Paulauskis JD, Sul HS. (1988). Cloning and expression of mouse fatty acid synthase and other specific mRNAs. Developmental and hormonal regulation in 3T3-L1 cells. J Biol Chem, 263:7049-54
120. Perea A, Vinambres C, Clemente F, et al. (1997). GLP-1 (7-36) amide: Effects on glucose transport and metabolism in rat adipose tissue. Hormone Metab Res, 29:417-21
121. Perrini S, Laviola L, Cignarelli A, et al. (2008). Fat depot-related differences in gene expression, adiponectin secretion, and insulin action and signalling in human adipocytes differentiated in vitro from precursor stromal cells. Diabetologia, 51:155-64
122. Pratley RE, Gilbert M. (2008). Targeting incretins in type 2 diabetes: Role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud, 5:73-94
123. Rangwala SM, Lazar MA. (2004). Peroxisome proliferator-Activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci, 25:331-6
124. Reginato MJ, Bailey ST, Krakow SL, et al. (1998). A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-Activated receptor gamma-Activating properties. J Biol Chem, 273:32679-84
125. Rocchi S, Picard F, Vamecq J, et al. (2001). A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell, 8:737-47
126. Rodbard HW, Jellinger PS, Davidson JA, et al. (2009). Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control. Endocr Pract, 15:540-59
127. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM. (2000). Transcriptional regulation of adipogenesis. Genes & Development, 14:1293-307
128. Rosmaninho-Salgado J, Marques AP, Estrada M, et al. (2012). Dipeptidyl-peptidase-IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-gamma expression. Peptides, 37:49-54
129. Ruiz-Grande C, Alarcon C, Merida E, Valverde I. (1992). Lipolytic action of glucagon-like peptides in isolated rat adipocytes. Peptides, 13:13-16
130. Sakoda H, Ogihara T, Anai M, et al. (2000). Dexamethasone-induced insulin resistance in 3T3-L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduction. Diabetes, 49:1700-8
131. Sancho V, Trigo MV, Gonzalez N, et al. (2005). Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. J Molec Endo, 35:27-38
132. Sancho V, Nuche B, Arnes L, et al. (2007). The action of GLP-1 and exendins upon glucose transport in normal human adipocytes, and on kinase activity as compared to morbidly obese patients. International J Molec Med, 19:961-6
133. Sewter CP, Blows F, Vidal-Puig A, O'Rahilly S. (2002). Regional differences in the response of human pre-Adipocytes to PPARgamma and RXRalpha agonists. Diabetes, 51:718-23
134. Shu Y, Sheardown SA, Brown C, et al. (2007). Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest, 117:1422-31
135. Smas CM, Sul HS. (1995). Control of adipocyte differentiation. Biochem J, 309:697-710
136. Smith SR, De Jonge L, Volaufova J, et al. (2005). Effect of pioglitazone on body composition and energy expenditure: A randomized controlled trial. Metab Clin Exp, 54:24-32
137. Søh;rensen AR, Stidsen CE, Ribel U, et al. (2010). Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor. Diabetes, Obesity & Metab, 12:665-73
138. Spiegelman BM. (1998). PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes, 47:507-14
139. Spiegelman BM, Flier JS. (1996). Adipogenesis and obesity: Rounding out the big picture. Cell, 87:377-89
140. Spiegelman BM, Frank M, Green H. (1983). Molecular cloning of mRNA from 3T3 adipocytes. Regulation of mRNA content for glycerophosphate dehydrogenase and other differentiation-Dependent proteins during adipocyte development. J Biol Chem, 258:10083-9
141. Stolic M, Russell A, Hutley L, et al. (2002). Glucose uptake and insulin action in human adipose tissue-influence of BMI, anatomical depot and body fat distribution. Inter J Obesity Related Metab Disord: J Inter Assoc for the Study of Obesity, 26:17-23
142. Swinnen SG, Simon AC, Holleman F, et al. (2011). Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews (Online), Jul 6;(7): CD006383
143. Szypowska A, Golicki D, Groele L, Pańkowska E. (2011). Long-Acting insulin analogueue detemir compared with NPH insulin in type 1 diabetes: A systematic review and meta-Analysis. Polskie Archiwum Medycyny Wewnetrznej, 121:237-46
144. Tafuri SR. (1996). Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes. Endocrinology, 137:4706-12
145. Taggart AKP, Kero J, Gan X, et al. (2005). (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem, 280:26649-52
146. Tai TA, Jennermann C, Brown KK, et al. (1996). Activation of the nuclear receptor peroxisome proliferator-Activated receptor gamma promotes brown adipocyte differentiation. J Biol Chem, 271:29909-14
147. Tan GD, Fielding BA, Currie JM, et al. (2005). The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia, 48:83-95
148. Tomiyama K, Nakata H, Sasa H, et al. (1995). Wortmannin, a specific phosphatidylinositol 3-kinase inhibitor, inhibits adipocytic differentiation of 3T3-L1 cells. Biochem Biophys Res Comm, 212:263-9
149. Tontonoz P, Hu E, Graves RA, et al. (1994a). mPPAR gamma 2: Tissuespecific regulator of an adipocyte enhancer. Genes Dev, 8:1224-34
150. Tontonoz P, Hu E, Spiegelman BM. (1994b). Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-Activated transcription factor. Cell, 79:1147-56
151. Tsunekawa T, Hayashi T, Suzuki Y, et al. (2003). Sulfonylurea agents exhibit peroxisome proliferator-Activated receptor gamma agonistic activity. Diabetes Care, 26:285-9
152. Tunaru S, Kero J, Schaub A, et al. (2003). PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med, 9:352-5
153. Tzivion G, Dobson M, Ramakrishnan G. (2011). FoxO transcription factors: Regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta, 1813:1938-45
154. Van Wijk JPH, De Koning EJP, Castro Cabezas M, Rabelink TJ. (2005). Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes. Diabetes Care, 28:844-9
155. Vendrell J, El Bekay R, Peral B, et al. (2011). Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology, 152:4072-9
156. Villanueva-Penacarrillo, ML, Marquez L, Gonzalez N, et al. (2001). Effect of GLP-1 on lipid metabolism in human adipocytes. Horm Metab Res, 33:73-7
157. Villanueva-Peñacarrillo ML, Puente J, Redondo A, et al. (2001). Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models. Endocrine, 15:241-8
158. Vilsboll T, Christensen M, Junker AE, et al. (2012). Effects of glucagonlike peptide-1 receptor agonists on weight loss: Systematic review and meta-Analyses of randomised controlled trials. BMJ (Clinical Research Ed), 344:d7771
159. Viollet B, Guigas B, Leclerc J, et al. (2009). AMP-Activated protein kinase in the regulation of hepatic energy metabolism: From physiology to therapeutic perspectives. Acta Physiologica (Oxford, England), 196:81-98
160. Wada T, Azegami M, Sugiyama M, et al. (2008). Characteristics of signalling properties mediated by long-Acting insulin analogueue glargine and detemir in target cells of insulin. Diab Res Clin Prac, 81: 269-77
161. Wang XZ, Ron D. (1996). Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 MAP Kinase. Science, 272:1347-9
162. Wang P, Renes J, Bouwman F, et al. (2007). Absence of an adipogenic effect of rosiglitazone on mature 3T3-L1 adipocytes: Increase of lipid catabolism and reduction of adipokine expression. Diabetologia, 50: 654-65
163. Wang Y, Kole HK, Montrose-Rafizadeh C, et al. (1997). Regulation of glucose transporters and hexose uptake in 3T3-L1 adipocytes: Glucagon-like peptide-1 and insulin interactions. J Molec Endocrin, 19:241-8
164. Wilson-Fritch L, Burkart A, Bell G, et al. (2003). Mitochondrial biogenesis and remodeling during adipogenesis and in response to the insulin sensitizer rosiglitazone. Mol Cell Biol, 23:1085-94
165. Wilson-Fritch L, Nicoloro S, Chouinard M, et al. (2004). Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest, 114: 1281-9
166. Wu Z, Xie Y, Morrison RF, Bucher NL, Farmer SR. (1998). PPARgamma induces the insulin-Dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes. J Clin Invest, 101:22-32
167. Yki-Järvinen H. (2004). Thiazolidinediones. New Eng J Med, 351: 1106-18
168. Zhou G, Myers R, Li Y, et al. (2001). Role of AMP-Activated protein kinase in mechanism of metformin action. J Clin Invest, 108:1167-74